Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL612325 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRSMN1; SMN2USP2LMNA | |
| SCHEMBL939773 | 0.84 | ALDH1A1 (0.47) | ALDH1A1TSHRSMN1; SMN2USP2LMNA | |
| SCHEMBL7825503 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TSHRSMN1; SMN2USP2LMNA | |
| SCHEMBL466295 | 0.78 | ALDH1A1 (0.56) | ALDH1A1TSHRSMN1; SMN2USP2LMNA | |
| Hydrochloric Acid SCHEMBL6578159 | 0.77 | ALDH1A1 (0.55) | ALDH1A1TSHRSMN1; SMN2USP2LMNA | |
| SCHEMBL14534858 | 0.75 | USP2 (0.62) | ALDH1A1TSHRSMN1; SMN2USP2LMNA | |
| SCHEMBL466314 | 0.75 | TSHR (0.62) | ALDH1A1TSHRSMN1; SMN2USP2LMNA | |
| SCHEMBL1643330 | 0.75 | TSHR (0.62) | ALDH1A1TSHRSMN1; SMN2USP2LMNA | |
| SCHEMBL6545165 | 0.75 | ALDH1A1 (0.38) | ALDH1A1TSHRSMN1; SMN2GAATDP1 | |
| Hydrochloric Acid SCHEMBL28038690 | 0.75 | ALDH1A1 (0.35) | ALDH1A1TSHRSMN1; SMN2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012164055-A2 | NEW COMPOUNDS, SYNTHESIS AND USE THEREOF IN THE TREATMENT OF PAIN | LACER, S.A. (ES) | 2012-12-06 | — | — | WO | disclosed |
| EP-2530072-A1 | New compounds, synthesis and use thereof in the treatment of pain | LACER, S.A. (ES) | 2012-12-05 | — | — | EP | disclosed |
| EP-2172445-A1 | Cis (z) 4-t-butylgabapentin and its synthesis | Hikal Limited (IN) | 2010-04-07 | — | — | EP | disclosed |
| US-7632864-B2 | Gabapentin analogues and process thereof | HIKAL LTD. (IN) | 2009-12-15 | — | — | US | disclosed |
| US-20070123591-A1 | Gabapentin analogues and process thereof | HIKAL LMITED INDIAN INSTITUE OF SCIENCE | 2007-05-31 | — | — | US | disclosed |
| EP-1763503-A1 | 4-T-BUTYLGABAPENTIN AND ITS SYNTHESIS | Hikal Limited (IN) | 2007-03-21 | — | — | EP | disclosed |
| WO-2005087709-A1 | 4-T-BUTYLGABAPENTIN AND ITS SYNTHESIS | HIKAL LIMITED (IN) | 2005-09-22 | — | — | WO | disclosed |
| US-20050209332-A1 | Gabapentin analogues and process thereof | HIKAL LIMITED | 2005-09-22 | — | — | US | disclosed |
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SOLCHEM ITALIANA S.P.A. (IT) | 2004-04-01 | — | — | US | disclosed |
| EP-1373186-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | Solchem Italiana S.p.A (IT) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003080588-A1 | CYCLIC 1-(ACYLOXY)-ALKYL PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2002074727-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | SOLCHEM ITALIANA S.P.A. (IT) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SLC7A1, MRPL21, BCAT1 | ALDH1A1 2987/4885TSHR 2582/4885SMN1; SMN2 2889/4885 |
| US-20070123591-A1 | Gabapentin analogues and process thereof | GABRB1, GABRB2, GABRB3 | ALDH1A1 1219/4885TSHR 1411/4885SMN1; SMN2 1271/4885 |
| US-20050209332-A1 | Gabapentin analogues and process thereof | GABRB1, GABRB2, GABRA4 | ALDH1A1 1807/4885TSHR 2467/4885SMN1; SMN2 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.